David Stamler

Biography

David Stamler, M.D., is the Chief Medical Officer and Senior Vice President, Clinical Development at Prana Biotechnology, based in San Francisco. Prior to joining Prana, Dr. Stamler worked for Teva Pharmaceuticals, as part of Teva’s US$3.5 billion acquisition of Auspex Pharmaceuticals.  Dr. Stamler led the development of a new drug for the treatment of Huntington’s disease, which was approved by the U.S. Food and Drug Administration (FDA) in April this year. This was the second neurological agent that Dr. Stamler has led through the approval process with the FDA. Dr. Stamler comes from Teva as VP, Clinical Development and Therapeutic Head, Movement Disorders where he was responsible for clinical-regulatory interactions leading to the approval of AUSTEDOTM (deutetrabenazine) for treatment of chorea associated with Huntington’s disease in 2017. Prior to Teva, Dr. Stamler was Chief Medical Officer at Auspex Pharmaceuticals, Inc. (which was acquired by Teva in 2015) and prior to this he served as Chief Medical Officer and Senior Vice President of Xenoport, Inc. where he led clinical development activities for their portfolio of CNS compounds.

Research Interest

Pharma & Healthcare